SYNTHESIS AND DOCKING STUDIES OF 2-(NITROOXY)-ETHYL-2-(SUBSTITUTED-2,5-DIPHENYL-OXAZOLE)-ACETATE AS ANTI-INFLAMMATORY AGENTS WITH ANALGESIC AND NITRIC OXIDE RELEASING PROPERTIES by Sarkate, Aniket P. & Shinde, Devanand B.
 
Original Article 
SYNTHESIS AND DOCKING STUDIES OF 2-(NITROOXY)-ETHYL-2-(SUBSTITUTED-2,5-
DIPHENYL-OXAZOLE)-ACETATE AS ANTI-INFLAMMATORY AGENTS WITH ANALGESIC AND 
NITRIC OXIDE RELEASING PROPERTIES 
 
ANIKET P. SARKATE, DEVANAND B. SHINDE* 
Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad 431004, MS, India 
Email: dbsaniket09@gmail.com       
 Received: 08 Jul 2015 Revised and Accepted: 08 Aug 2015 
ABSTRACT 
Objective: The objective of the reported study was to develop new chemical entities as potential anti-inflammatory agents with analgesic and nitric 
oxide releasing properties. 
Methods: The compounds were designed with the help of docking studies. In the synthetic study the target compounds were obtained by reacting 2-
(substituted-2,5-diphenyl-oxazole)-acetic acid (2a-2v) with nitro-oxy ethyl bromide in the presence of dimethyl formamide and potassium carbonate to 
give 2-(nitrooxy) ethyl 2-(substituted-2,5-diphenyl-oxazole) acetate derivatives (3a-3v). The synthesized derivatives were characterized with the help of 
different analytical techniques and further evaluated for anti-inflammatory, analgesic and nitric oxide releasing activity. 
Results: With the help of docking study it was proven that compounds 3a, 3c, 3g, 3l and 3r showed significant G-score. In the anti-inflammatory and 
analgesic study also, compounds 3a, 3c, 3g, 3l and 3r exhibited promising activity. All the synthesized compounds exhibited significant nitric oxide 
releasing properties both in-vitro and in-vivo.  
Conclusion: Compounds 3a, 3c, 3g, 3l and 3r exhibited prominent anti-inflammatory and analgesic activity. 
Keywords: Oxazole, Docking, Anti-inflammatory, Analgesic, Nitric oxide. 
 
INTRODUCTION 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are mainly used for 
reduction in the inflammation and fever. Selective Cyclo-oxygenase-
2 (COX-2) inhibitors show less or no GI damage and bleeding 
compared with conventional NSAIDs [1]. As per reports, the 
selective COX-2 inhibitors cause significant adverse effects on the 
renal and cardiovascular systems. To minimize the side effects of 
NSAIDs, recent strategies adopted the use of the dual LOX/COX 
inhibitors, COX inhibitors with a nitric oxide-releasing functional 
group and other approaches [2-4]. 
Oxazole derivatives have raised considerable attention to medicinal 
research. Among the numerous heterocyclic moieties of biological 
and pharmacological interest, the oxazole ring is endowed with 
various activities, such as analgesic, anti-inflammatory [5], 
hypoglycemic [6] and antibacterial [7] activities. Oxazoles are also 
one of the key building elements of the natural products.  
In the present work, synthetic approaches based on chemical 
modification of NSAIDs have been taken with the aim of improving 
safety profile and in turn therapeutic window of the resultant NSAIDs. 
Our previous studies had described the synthesis of hybrid molecules 
with nitric oxide-releasing group that resulted in an increased anti-
inflammatory activity with reduced GI-ulcerogenicity [1]. In our 
attempt to continue to discover new, safer, and potent agents for the 
treatment of inflammatory diseases, we have synthesized compounds 
containing pharmacophore of 2, 5 diaryl oxazole ring with nitric oxide-
releasing group to accentuate potency and reduce toxicities associated 
with the traditional NSAIDs. The compounds designed so were found 
to possess much significant anti-inflammatory activity with analgesic 
and nitric oxide releasing properties. 
MATERIALS AND METHODS 
Synthetic studies 
All the compounds were synthesized using the reported literature 
procedures. Synthetic procedures were set and optimized as and 
were required. All the chemicals and solvents were purchased from 
avra chemicals and sigma-aldrich. Melting points were uncorrected 
and recorded on optimelt digital melting point apparatus. IR spectra 
were recorded on bruker alpha E FTIR spectrophotometer.1H NMR 
were recorded on varian 400MHz spectrometer by using TMS as 
internal standard and DMSO as a solvent. Mass spectra were 
recorded on scinpor Q-TOF.  
General procedure for the synthesis of substituted benzoyl 
propionic acid (1a-1v)  
In a 250 ml RBF, 0.68 mol of succinic anhydride and 4.5 mol of 
benzene were placed. In the reaction mixture 1. 5 mol of powdered, 
anhydrous aluminum chloride were added all at once. The reaction 
mixture was refluxed, with continued stirring, for half an hour. After 
heating, cold water was added drop wise to the reaction mixture. 
The excess benzene was removed by steam distillation and the hot 
solution was at once poured into a beaker. After the mixture was 
cold the liquid was decanted from the precipitated solid and 
acidified with concentrated hydrochloric acid. Desired product was 
separated and filtered. 
Synthesis of nitrooxy ethyl bromide  
2-bromoethanol (10 mmol) was added drop wise to a solution of 
70% HNO3 (1.1 ml) and 95% H2SO4 (2.4 ml) at 0 °C, and the reaction 
was allowed to proceed at the same temperature for 1 h with 
stirring. The resulting suspension was poured into water (50 ml), 
extracted with CH2Cl2 (3 × 200 ml), and dried over MgSO4, and the 
solvent was removed to give the nitrooxy alkyl bromide [8]. 
General procedure for the synthesis of 2-(substituted-2,5-
diphenyl-oxazole)-acetic acid (2a-2v) 
To a solution of benzylamine (1.5 mmol) in DMF (3 ml) was 
successively added iodine (1.2 mmol), benzoyl propionic acid (1 
mmol), Cu (OAc)2. H2O (0.1 mmol), TBHP (2 mmol). After the 
reaction mixture was stirred for 5 h at room temperature, other 
portion of benzylamine (0.5 mmol) were added to the reaction 
system again. Upon completion, the reaction mixture was extracted 
with EtOAc, dried over Na2SO4. Then the organic phase was 
concentrated in vacuum and purified by silica gel column 
chromatography to afford the desired product [9]. 
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General procedure for the synthesis of 2-(nitrooxy) ethyl 2-
(substituted-2,5-diphenyl-oxazole) acetate derivatives (3a-3v) 
A solution of the nitrooxy ethyl bromide (0.22 mmol), 2a (0.20 
mmol), and K2CO3 (0.24 mmol) in dry DMF (10 ml) was stirred at 25 
°C for 24 h. Water (20 ml) was added, the mixture was extracted 
with EtOAc (3 × 30 ml), the extract was washed with water (2 × 20 
ml) and then brine (20 ml), the organic phase was dried over Na2SO4, 
and the solvent was removed under vacuum. The residue was 
purified by column chromatography (hexane/ethyl acetate) to afford 
the desired product [8]. 
Analytical data 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-fluorophenyl) 
oxazol-4-yl) acetate (3a) 
White solid; IR: 3028, 2847, 1745, 1525, 1626, 1610 cm-1;1HNMR 
(400 MHz, DMSO): δ= 4.25 (s,2H,CH), 4.6(t,2H,CH2), 4.8 (t,2H,CH2), 
7.01 (d,2H,CH), 7.25 (d,2H,CH), 7.40 (d,2H, CH), 7.5 (d,2H,CH). MS: 
m/z 421[M+H]+. Elemental analysis: Found C(54.25), H(3.36), N 
(6.67) Calculated C(54.23), H(3.35), N(6.66). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-methoxy phenyl) 
oxazol-4-yl) acetate (3b) 
Reddish orange solid; IR: 3055, 2810, 1721, 1539, 1595, 1210, 1629 cm-
1;1HNMR (400 M Hz, DMSO): δ= 3.6 (t, 2H, CH2), 4.6 (t, 2H, CH2), 4.78 (t, 
3H, CH3), 4.25 (s, 2H, CH), 7.25 (t, 2H, CH), 7.41 (d, 2H, CH), 7.6 (t, 2H, 
CH), 7.65 (d, 2H, CH) MS: m/z 433[M+H]+. Elemental analysis: Found 
C(55.49), H(3.98), N(6.49) Calculated C(55.50), H(3.96), N(6.47). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(3-methoxy phenyl) 
oxazol-4-yl)acetate (3c) 
White solid; IR: 3045, 2829, 1726, 1510, 1623, 1225, 1639 cm-
1;1HNMR (400 MHz, DMSO):): δ= 3.7 (t, 2H, CH2), 4.5 (t, 2H, CH2), 
4.82 (s, 3H, CH3), 4.2 (s, 2H, CH), 7.22 (t, 2H, CH), 7.3 (d, 2H, CH), 7.5 
(t, 2H, CH), 7.6 (d, 2H, CH). MS: m/z 433 [M+H]+. Elemental analysis: 
Found C (55.52), H(3.98), N(6.49) Calculated C(55.50), H(3.96), 
N(6.47). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(3-methoxybenzyl) 
oxazol-4-yl) acetate (3d) 
Off white solid; IR: 3022,2856,1710,1539,1580,1235,1659 cm-
1;1HNMR (400MHz, DMSO): δ= 3.82(t,2H,CH2), 4.55(t,2H,CH2), 
4.64(s,3H,CH3), 4.25(s,2H,CH2), 4.1(s,2H,CH2), 7.0 
(d,2H,CH),7.0(s,1H,CH),7.44(d,2H,CH),7.64(s,1H,CH), 7.68(d,2H,CH). 
MS: m/z 447[M+H]+. Elemental analysis: Found C(56.46), H(4.27), 
N(6.29) Calculated C(56.45), H(4.29), N(6.27). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(furan-2-yl)oxazol-
4-yl)acetate (3e) 
Yellow solid; IR: 3068, 2830, 1723, 1546, 1565, 1599 cm-1;1H NMR 
(400 MHz, DMSO): δ= 4.1 (t, 2H, CH2), 4.3 (t, 2H, CH2), 4.45 (t, 2H, 
CH2), 7.0 (s, 1H, CH), 7.1 (s, 1H, CH), 7.5 (d, 2H, CH), 7.6 (d, 2H, CH), 
7.8 (s, 1H, CH). MS: m/z 393 [M+H]+. Elemental analysis: Found 
C(51.95), H (3.34), N (7.11) Calculated C(51.99), H(3.34), N(7.13). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(pyridin-2-yl) 
oxazol-4-yl) acetate (3f) 
White solid; IR: 3102, 2813, 1739, 1535, 1549, 1629 cm-1;1HNMR 
(400 MHz, DMSO): δ= 3.8 (t, 2H, CH2), 4.5 (t, 2H, CH2), 5.0 (t, 2H, 
CH2), 7.5 (d, 2H, CH), 7.6 (d, 2H, CH), 7.7 (s, 1H, CH), 7.75 (s, 1H, CH), 
7.8 (s, 1H, CH), 7.9 (s, 1H, CH). MS: m/z 404[M+H]+. Elemental 




Off white solid; IR: 3056, 2840, 1750, 1520, 1559, 1656 cm-1;1H NMR 
(400 MHz, DMSO): δ= 3.7 (t, 2H, CH2), 4.3 (t, 2H, CH2), 4.9 (t, 2H, 
CH2), 7.4 (d, 2H, CH), 7.42 (s, 1H, CH), 7.5 (d, 2H, CH), 7.7 (d, 2H, CH), 
7.9 (d, 2H, CH). MS: m/z 403[M+H]+. Elemental analysis: Found C 
(56.68), H(3.77), N(6.93) Calculated C(56.66), H(3.75), N(6.95). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-ethoxyphenyl) 
oxazol-4-yl) acetate (3h) 
Pale yellow solid; IR: 3041, 2829, 1740, 1514, 1559, 1244, 1636 cm-
1;1H NMR (400 MHz, DMSO): δ= 1.4 (t,3H,CH3), 3.7 (s,2H,CH2), 3.84 
(t,2H,CH2), (3.9 (t,2H,CH2), 4.1 (q,2H, CH2), 7.1 (d,2H,CH), 7.4 
(d,2H,CH), 7.7 (d, 2H, CH), 7.9 (d, 2H, CH). MS: m/z 447 [M+H]+. 
Elemental analysis: Found C (56.47), H(4.27), N(6.29) Calculated 
C(56.45), H(4.29), N(6.27). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-(trifluoro -
methoxy) phenyl) oxazol-4-yl) acetate (3i) 
Buff solid; IR: 3031, 2822, 1729, 1522, 1542, 1219, 1650 cm-
1;1HNMR(400 MHz, DMSO): δ= 3.7 (s, 2H, CH2), 4.1 (t, 2H, CH2), 4.3 (t, 
2H, CH2), 7.1 (d, 2H, CH), 7.42 (d, 2H, CH), 7.7 (d, 2H, CH), 7.9 (d, 2H, 
CH). MS: m/z 487[M+H]+. Elemental analysis: Found C(49.37), 
H(2.88), N (5.79) Calculated C(49.35), H(2.90), N(5.75). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-((trifluoro-methyl) 
thio) phenyl) oxazol-4-yl) acetate (3j) 
White solid; IR: 3021, 2835, 1729, 1525, 1549, 1661 cm-
1;1HNMR(400 MHz, DMSO): δ= 3.6 (s, 2H, CH2), 4.2 (t, 2H, CH2), 4.4 (t, 
2H, CH2), 7.2 (d, 2H, CH), 7.5 (d, 2H, CH), 7.6 (d, 2H, CH), 7.8 (d, 2H, 
CH). MS: m/z 503 [M+H]+. Elemental analysis: Found C(47.79), 
H(2.83), N(5.60) Calculated C(47.77), H(2.81), N(5.57). 
2-(nitrooxy) ethyl-2-(5-(4-chlorophenyl)-2-(4-(difluoro-methoxy) 
phenyl) oxazol-4-yl) acetate (3k) 
Off buff solid; IR: 3052, 2830, 1721, 1532, 1553, 1229, 1631 cm-1;1H 
NMR (400 MHz, DMSO): δ= 3.6 (s, 2H, CH2), 4.1 (t, 2H, CH2), 4.3 (t, 
2H, CH2), 7.1 (s, 1H, CH), 7.2 (d, 2H, CH), 7.5 (d, 2H, CH), 7.6 (d, 2H, 
CH), 7.9 (d, 2H, CH). MS: m/z 469 [M+H]+. Elemental analysis: Found 
C (51.25), H (3.24), N (5.97) Calculated C (51.24), H (3.23), N (5.98). 
2-(nitrooxy) ethyl-2-(2-(4-fluorophenyl)-5-(p-tolyl) oxazol-4-
yl) acetate (3l) 
Off white solid; IR: 3011, 2830, 1736, 1520, 1541, 1644 cm-1;1H NMR 
(400 MHz, DMSO): δ= 1.9 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.12 (t, 2H, 
CH2), 4.2 (t, 2H, CH2), 7.2 (d, 2H, CH), 7.3 (d, 2H, CH), 7.6 (d, 2H, CH), 
7.9 (d, 2H, CH). MS: m/z 401 [M+H]+. Elemental analysis: Found C 
(60.01), H (4.29), N (7.02) Calculated C (60.00), H (4.28), N (7.00). 
2-(nitrooxy) ethyl-2-(2-(4-methoxyphenyl)-5-(p-tolyl) oxazol-4-
yl) acetate (3m) 
Yellow solid; IR: 3063, 2810, 1739, 1519, 1544, 1209, 1649 cm-
1;1HNMR (400 MHz, DMSO): δ= 2.1 (s, 3H, CH3), 3.7(s,3H,CH3), 
3.6(s,2H,CH2), 4.2(t,2H,CH2), 4.6(t,2H, CH2), 7.1(d,2H,CH), 7.2(d,2H, 
CH), 7.5 (d, 2H,CH), 7.7 (d,2H,CH). MS: m/z 413[M+H]+. Elemental 
analysis: Found C(61.15), H(4.88), N(6.81) Calculated C(61.16), H 
(4.89), N (6.79). 
2-(nitrooxy) ethyl-2-(2-(3-methoxyphenyl)-5-(p-tolyl) oxazol-4-
yl) acetate (3n) 
Off white solid; IR: 3029,2821,1726,1550,1565,1222,1665 cm-
1;1HNMR (400 MHz, DMSO): δ= 2.1(s,3H,CH3), 
3.6(s,2H,CH2),3.7(s,3H,CH3),4.1(t,2H,CH2), 4.2(t,2H,CH2), 7.0 (s,1H,CH), 
7.2(d,2H,CH),7.4(d,2H,CH), 7.5(d,2H,CH),7.52(s,1H,CH). MS: m/z 413 
[M+H]+. Elemental analysis: Found C(61.16), H(4.90), N(6.80) 
Calculated C(61.16), H (4.89), N(6.79). 
2-(nitrooxy) ethyl-2-(2-(3-methoxybenzyl)-5-(p-tolyl) oxazol-4-
yl) acetate (3o) 
Yellow solid; IR: 3041, 2809, 1739, 1521, 1544, 1250, 1639 cm-
1;1HNMR (400 MHz, DMSO): δ= 2.1 (s, 3H, CH3), 3.7 (s, 2H, CH2), 3.72 
(s, 3H, CH3), 3.8 (s, 2H, CH2), 3.9 (t, 2H, CH2), 4.1 (t, 2H, CH2), 6.9 (d, 
2H, CH), 7.0 (s, 1H, CH), 7.2 (d, 2H, CH), 7.4 (s, 1H, CH), 7.5 (d, 2H, 
CH). MS: m/z 427 [M+H]+. Elemental analysis: Found C (61.99), H 
(5.18), N (6.59) Calculated C (61.97), H (5.20), N (6.57). 
2-(nitrooxy) ethyl-2-(2-(furan-2-yl)-5-(p-tolyl) oxazol-4-yl) 
acetate (3p) 
White solid; IR: 3059, 2833, 1759, 1519, 1550, 1640 cm-1;1HNMR 
(400 MHz, DMSO): δ= 2.2 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.1 (t, 2H, 
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CH2), 4.5 (t, 2H, CH2), 6.9 (s, 1H, CH), 7.0 (s, 1H, CH), 7.2 (d, 2H, CH), 
7.5 (d, 2H, CH), 7.7 (s, 1H, CH). MS: m/z 373 [M+H]+. Elemental 
analysis: Found C (58.05), H (4.29), N (7.55) Calculated C (58.06), H 
(4.33), N (7.52). 
2-(nitrooxy) ethyl-2-(2-(pyridin-2-yl)-5-(p-tolyl) oxazol-4-
yl)acetate (3q) 
Grey solid; IR: 3029, 2810, 1749, 1530, 1559, 1655 cm-1;1HNMR (400 
MHz, DMSO): δ= 2.2 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.2 (t, 2H, CH2), 4.6 
(t, 2H, CH2), 7.1 (d, 2H, CH), 7.4 (s, 1H, CH), 7.5 (d, 2H, CH), 7.9 (s, 1H, 
CH), 8.0 (d, 2H, CH). MS: m/z 384 [M+H]+. Elemental analysis: Found 
C (59.55), H (4.49), N (10.97) Calculated C (59.53), H (4.47), N 
(10.96). 
2-(nitrooxy) ethyl-2-(2-phenyl-5-(p-tolyl) oxazol-4-yl) acetate 
(3r) 
Off white solid; IR: 3041, 2822, 1730, 1529, 1560, 1660 cm-1;1HNMR 
(400 MHz, DMSO) δ= 2.2 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.2 (t, 2H, CH2), 4.7 
(t, 2H, CH2), 7.2 (d, 2H, CH), 7.4 (s, 1H, CH), 7.5 (d, 2H, CH), 7.6 (d, 2H, CH), 
8.1 (d, 2H, CH). MS: m/z 383 [M+H]+. Elemental analysis: Found C 
(62.80), H (4.72), N (7.31) Calculated C (62.82), H (4.74), N (7.33). 
2-(nitrooxy) ethyl-2-(2-(4-ethoxyphenyl)-5-(p-tolyl)oxazol-4-
yl)acetate (3s) 
White solid; IR: 3051, 2819, 1720, 1530, 1566, 1228, 1645 cm-
1;1HNMR(400MHz, DMSO): δ= 1.4 (t,3H,CH3), 2.25 (s,3H,CH3), 3.6 
(s,2H,CH2), 3.9 (t,2H,CH2), 4.2 (t,2H,CH2), 4.4 (q, 2H,CH2), 7.1 
(d,2H,CH), 7.3 (d,2H,CH), 7.5 (d,2H,CH), 8.0 (d,2H, CH). MS: 
m/z427[M+H]+. Elemental analysis: Found C(61.99), H(5.17),N(6.59) 
Calculated C(61.97), H(5.20), N (6.57). 
2-(nitrooxy) ethyl-2-(5-(p-tolyl)-2-(4-(trifluoromethoxy) 
phenyl) oxazol-4-yl) acetate (3t) 
White solid; IR: 3070, 2823, 1719, 1509, 1535, 1229, 1605 cm-
1;1HNMR(400 MHz,DMSO): δ= 2.3 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.2 (t, 
2H, CH2), 4.9 (t, 2H, CH2), 7.0 (d, 2H, CH), 7.2 (d, 2H, CH), 7.5 (d, 2H, 
CH), 8.0 (d, 2H, CH). MS: m/z 467[M+H]+. Elemental analysis: Found 
C(54.10), H(3.69), N(6.03) Calculated C(54.08), H(3.67), N(6.01). 
2-(nitrooxy) ethyl-2-(5-(p-tolyl)-2-(4-((trifluoromethyl) thio) 
phenyl) oxazol-4-yl) acetate (3u) 
Yellow solid; IR: 3029, 2844, 1730, 1530, 1565, 1625 cm-
1;1HNMR(400MHz,DMSO): δ= 2.25 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.1 
(t, 2H, CH2), 4.3 (t, 2H, CH2), 7.2 (d, 2H, CH), 7.5 (d, 2H, CH), 7.6 (m, 
4H, CH). MS: m/z 483[M+H]+. Elemental analysis: Found C(52.30), 
H(3.57), N(5.83) Calculated C(52.28), H(3.55), N(5.81). 
2-(nitrooxy) ethyl 2-(2-(4-(difluoromethoxy) phenyl)-5-(p-
tolyl) oxazol-4-yl)acetate (3v) 
Buff solid; IR: 3023, 2822, 1729, 1525, 1540, 1252, 1657 cm-
1;1HNMR(400 MHz, DMSO): δ= 2.3 (s, 3H, CH3), 3.6 (s, 2H, CH2), 4.3 (t, 
2H, CH2), 4.7 (t, 2H, CH2), 7.05 (s, 1H, CH), 7.0 (d, 2H, CH), 7.2 (d, 2H, 
CH), 7.6 (d, 2H, CH), 7.9 (d, 2H, CH). MS: m/z 449 [M+H]+. Elemental 
analysis: Found C(56.26), H(4.07), N(6.27) Calculated C(56.25), 
H(4.05), N(6.25). 
Pharmacology 
All the method for pharmacological work has been performed as per 
our previously published work [1]. 
Docking methodology 
Molecular docking studies were performed using Glide v6.2 
(Schrödinger, LLC). The coordinates for COX-2 enzyme were taken 
from RCSB Protein Data Bank (PDB Id. 1CX2) and prepared for 
docking using protein preparation wizard. Water molecules in the 
structure were removed and termini were capped by adding ACE 
and NMA residue. The bond orders and formal charges were added 
for hetero groups and hydrogens were added to all atoms in the 
structure. Side chains that were not close to the binding cavity and 
do not participate in salt bridges were neutralized. After 
preparation, the structures were refined to optimize the hydrogen 
bond network using OPLS_2005 force field. This helps in 
reorientation of the side chain hydroxyl group. The minimization 
was terminated when the energy converged or the RMSD reached a 
maximum cut off of 0.30 Å. Grids were then defined around refined 
structure by centering on ligand using default box size. The extra 
precision (XP) docking mode for compounds, optimized by Ligprep, 
was performed on the generated grid of protein structure [10]. 
RESULTS AND DISCUSSION 
Chemistry 
The synthesis of target compounds 3a-3v is shown in scheme 1-2. 
Succinic anhydride was reacted with substituted benzene in the 
presence of aluminium chloride to afford substituted benzoyl 
propionic acid (1a-1v). Nitro-oxy ethyl bromide was prepared from 
bromoethanol in the presence of nitric acid and sulfuric acid. 
Substituted benzoyl propionic acid was reacted with substituted 
benzyl amines in the presence of TBHP, copper acetate, iodine and 
dimethyl formamide to give 2-(substituted-2,5-diphenyl-oxazole)-
acetic acid (2a-2v). The target compounds were obtained by reacting 
2-(substituted-2,5-diphenyl-oxazole)-acetic acid with nitro-oxy ethyl 
bromide in the presence of dimethyl formamide and potassium 
carbonate to give2-(nitrooxy)-ethyl-2-(substituted-2,5-diphenyl-
oxazole)acetate derivatives (3a-3v, table 1). The structures of 
various synthesized compounds were assigned on the basis of 
results of different chromatographic and spectral studies. The 
physical data, FTIR, 1H-NMR, mass spectral data and elemental 




Scheme 1: Synthesis of intermediate nitro-oxy ethyl bromide. 
Reagents and conditions (a) 70% HNO3, 95% H2SO4, 0 °C, 1 h 
 
 
Scheme 2: Synthesis of compounds 3a-3v. Reagents and 
conditions (a) AlCl3 (b) Substituted benzyl amines, TBHP, 
Cu(OAC)2, I2, DMF, rt for 6 h (c) O2NO-CH2-CH2-Br, DMF, K2CO3, 
25 °C, 24 h 
 
Pharmacology 
The synthesized compounds were subjected to the evaluation of 
anti-inflammatory, analgesic and nitric oxide-releasing properties. 
Celecoxib was used as reference standard.  
Anti-inflammatory activity 
Anti-inflammatory activity of the synthesized compounds was 
evaluated by carrageenan-induced rat paw edema model (table 2). 
Out of the synthesized compounds 3a, 3c, 3g, 3l and 3r (66.82–
69.26%) exhibited very significant anti-inflammatory activity 
compared to standard drug celecoxib (69.26 % at 3 h). Thus, the 
compounds having a substitution of fluoro and methoxy group on 
aryl ring and substitution of chloro and a methyl group at R position 
(3a, 3c and 3l) show equipotent activity with celecoxib. Compound 
3g and 3r also shows equipotent activity in which aryl ring is un 
susbstituted and chloro and a methyl group at R position. Compound 
3d and 3e shows decreased anti-inflammatory activity (In 
compound 3d, aryl ring is separated from the oxazole ring with one 
carbon atom with methoxy substitution and R position is substituted 
by chloro group. In compound 3e aryl ring is replaced by a furan 
ring, whereas R position is substituted by chloro group). As 
compared to our previously reported work [1], there is significant 
rise in the anti-inflammatory activity of the current work. 
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Table 1: Characterization data for synthesized compounds (3a-3v) 
S. No. Entry Ar R MF MW % yield MP( °C) 
1 3a 4-FC6H4 4-Cl C19H14ClFN2O6 420 85 198-199 
2 3b 4-CH3OC6H4 4-Cl C20H17ClN2O7 432 83 209-210 
3 3c 3-CH3OC6H4 4-Cl C20H17ClN2O7 432 74 222-223 
4 3d 
 
4-Cl C21H19ClN2O7 446 70 233-234 
5 3e 
 
4-Cl C17H13ClN2O7 392 65 185-186 
6 3f 
 
4-Cl C18H14ClN3O6 403 67 205-206 
7 3g C6H5 4-Cl C19H15ClN2O6 402 90 213-215 
8 3h 4-C2H5OC6H4 4-Cl C21H19ClN2O7 446 80 228-229 
9 3i 4-CF3OC6H4 4-Cl C20H14ClF3N2O7 486 83 246-247 
10 3j 4-CF3SC6H4 4-Cl C20H14ClF3N2O6S 502 79 240-241 
11 3k 4-CF2HOC6H4 4-Cl C20H15ClF2N2O7 468 86 230-231 
12 3l 4-FC6H4 4-CH3 C20H17FN2O6 400 92 193-194 
13 3m 4-CH3OC6H4 4-CH3 C21H20N2O7 412 81 221-222 
14 3n 3-CH3OC6H4 4-CH3 C21H20N2O7 412 71 179-180 
15 3o 
 
4-CH3 C22H22N2O7 426 67 185-186 
16 3p 
 
4-CH3 C18H16N2O7 372 65 167-168 
17 3q 
 
4-CH3 C19H17N3O6 383 68 177-179 
18 3r C6H5 4-CH3 C20H18N2O6 382 88 152-153 
19 3s 4-C2H5OC6H4 4-CH3 C22H22N2O7 426 77 199-200 
20 3t 4-CF3OC6H4 4-CH3 C21H17F3N2O7 466 82 224-225 
21 3u 4-CF3SC6H4 4-CH3 C21H17F3N2O6S 482 84 236-237 
22 3v 4-CF2HOC6H4 4-CH3 C21H18F2N2O7 448 86 210-211 
 
Table 2: Results of anti-inflammatory activity of synthesized compounds (3a-3v) against carrageenan-induced rat paw edema model in rats 
Comp 
Code 
Change in paw volume in (ml) after drug 
Treatment (±SEM) 
Anti-inflammatory activity (% Inhibition) 
 1h 2h 3h 1h 2h 3h 
Control 1.70±0.031** 1.89±0.019** 2.05±0.023** - - - 
Celecoxib 0.68±0.060** 0.66±0.056** 0.63±0.052** 60 65.07 69.26 
3a 0.70±0.029** 0.66±0.088** 0.63±0.040** 58.82 65.07 69.26 
3b 0.86±0.018** 0.83±0.033** 0.80±0.087** 49.41 56.08 60.97 
3c 0.79±0.047** 0.76±0.09** 0.64±0.050** 53.52 59.78 68.78 
3d 1.10±0.022** 1.13±0.082** 1.15±0.038** 35.29 40.21 43.90 
3e 1.11±0.085** 1.14±0.021** 1.17±0.042** 34.70 39.68 42.92 
3f 0.77±0.024** 0.74±0.029** 0.72±0.013** 54.70 60.84 64.87 
3g 0.75±0.025** 0.71±0.028** 0.68±0.049** 55.88 62.43 66.82 
3h 0.83±0.031** 0.80±0.035** 0.77±0.027** 51.17 57.67 62.43 
3i 0.87±0.036** 0.85±0.039** 0.82±0.033** 48.82 55.02 60.00 
3j 0.81±0.033** 0.78±0.069** 0.76±0.045** 52.35 58.73 62.92 
3k 0.82±0.041** 0.79±0.061** 0.77±0.057** 51.76 58.20 62.43 
3l 0.69±0.022** 0.67±0.097** 0.65±0.044** 59.41 64.55 68.29 
3m 0.90±0.055** 0.86±0.039** 0.82±0.015** 47.05 54.49 60.00 
3n 0.91±0.063** 0.89±0.030** 0.86±0.024** 46.47 52.91 58.04 
3o 1.01±0.090** 1.04±0.087** 1.07±0.022** 40.58 44.97 47.80 
3p 1.08±0.065** 1.10±0.095** 1.12±0.033** 36.47 41.79 45.36 
3q 1.05±0.023** 1.08±0.020** 1.11±0.061** 38.23 42.85 45.85 
3r 0.73±0.076** 0.71±0.082** 0.68±0.055** 57.05 62.43 66.82 
3s 1.02±0.064** 1.00±0.064** 0.98±0.066** 40.00 47.08 52.19 
3t 0.90±0.079** 0.87±0.077** 0.85±0.073** 47.05 53.96 58.53 
3u 1.11±0.075** 1.07±0.025** 1.04±0.090** 34.70 43.38 49.26 
3v 0.80±0.060** 0.77±0.057** 0.73±0.060** 52.94 59.25 64.39 
Data analyzed by one way ANOVA followed by Dunnett’s ‘t’ test, (n = 6), * P<0.05, ** P<0.01 significant from control ns not significant 
 
Analgesic activity 
The analgesic activity of the synthesized compounds was studied by 
using acetic acid-induced writhing test in mice (table 3). The 
analgesic effect of compounds 3a, 3g, 3l and 3r (63.90-66.71%) were 
found to be equipotent compared to standard drug celecoxib 
(66.75%) similar to anti-inflammatory activity. Compound 3d shows 
least analgesic activity similar to anti-inflammatory activity. As 
compared to our previously reported work [1], there is significant 
rise in the analgesic activity of the current work.  
Nitric oxide-release study 
In isolated wistar rat aorta rings, compounds 3a-3v competitively 
inhibited norepinephrine-induced contraction effects, causing a shift 
to the right of the norepinephrine concentration response curves. 
EC50 (µg/ml) values were calculated from the cumulative 
concentration response curves. In order to prove the involvement of 
nitric oxide in the relaxation process, nitric oxide-releasing 
properties of synthesized compounds were assessed in phosphate 
buffer, pH 7.4, in the presence of L-cysteine, relative to nitric oxide 
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released from standard sodium nitrite solution (table 4). From in 
vitro nitric oxide releasing data, it is observed that compound 3c 
shows potent nitric oxide releasing properties, whereas compound 
3b shows less nitric oxide releasing properties. From nitric oxide 
releasing activity of rat aortic muscle, it is observed that compound 
3g shows potent EC50 values whereas compound 3e shows less EC50 
value. As compared to our previously reported work [1], we got 
better EC50 and % NO release values of the current work. 
 
Table 3: Results of analgesic activity of synthesized compounds (3a-3v) against acetic acid-induced writhing test in mice 
Compound 
Code 










Control 27.37±0.47** - 3k 10.67±0.32** 61.01 
Celecoxib 9.01±0.35** 66.75 3l 9.11±0.10** 66.71 
3a 9.45±0.84** 65.47 3m 13.65±0.23** 50.12 
3b 11.20±0.65** 59.07 3n 11.56±0.39** 57.76 
3c 10.51±0.19** 61.60 3o 13.88±0.27** 49.28 
3d 14.99±0.11** 45.23 3p 14.02±0.63** 48.77 
3e 14.35±0.63** 47.57 3q 14.10±0.29** 48.48 
3f 10.45±0.45** 61.81 3r 9.23±0.12** 66.27 
3g 9.88±0.80** 63.90 3s 10.96±0.22** 59.95 
3h 10.25±0.51** 62.55 3t 11.45±0.07** 58.16 
3i 12.77±0.55** 53.34 3u 14.15±0.72** 48.30 
3j 10.89±0.46** 60.21 3v 10.35±0.83** 62.18 
Data analyzed by one way ANOVA followed by Dunnett’s ‘t’ test,(n = 6), ** P<0.01 significant from control 
 
Table 4: EC50 values and nitric oxide-releasing properties of the compounds (3a–3v) 
S. No. Compound Code EC50 % NO release S. No. Compound Code EC50 % NO release 
1 3a 39.59 0.55 12 3l 35.88 0.69 
2 3b 43.85 0.28 13 3m 47.51 0.36 
3 3c 42.75 0.73 14 3n 49.22 0.30 
4 3d 36.56 0.29 15 3o 31.07 0.34 
5 3e 58.22 0.38 16 3p 40.44 0.56 
6 3f 49.87 0.66 17 3q 42.43 0.64 
7 3g 29.65 0.59 18 3r 50.63 0.47 
8 3h 33.54 0.37 19 3s 48.48 0.50 
9 3i 41.21 0.44 20 3t 46.90 0.58 
10 3j 39.57 0.51 21 3u 55.45 0.44 
11 3k 51.23 0.70 22 3v 43.22 0.70 
 
Docking study 
In all series, the docking poses of compounds showing higher 
docking score (G-score) were compared with that of standard 
celecoxib in the active site of the COX-2 enzyme. The docking study 
of oxazole derivatives showed that all compounds were 
successfully docked in the active site of the COX-2 enzyme and 
acquired the same binding poses (‘V’ shaped) as that by celecoxib 
(fig 1). Due to having diaryl ring attached to middle hetero ring in 
oxazole derivatives, they show desired binding pose in the binding 
pocket of the COX-2 enzyme. Fig. (fig 2 and fig 3) showed that 
diaryl rings are surrounded by hydrophobic amino acids Val 349, 
Leu 359, Met 113, Val 116, Leu 513, Ala 527, Trp 387, Leu 384, Met 
522, Phe 518, Tyr 385, Phe 318, Leu 117, and Tyr 355 and thus 
help to stabilize the compounds in the active site of COX-2 enzyme. 
The long aliphatic side chain in between two diaryl ring at C5 
position made the hydrogen bond with Arg 513 and Tyr 355 and 
thus favors the stability of oxazole derivatives. The substitution 
patterns at Ar position is mainly responsible for variation in the G-
score and binding poses of oxazole derivatives in the active site of 
the COX-2 enzyme and thus affect the binding affinity of each 
compound toward COX-2 enzyme. The compounds 3a, 3g, 3l and 3r 
containing F or CH3 substituted phenyl ring at Ar position showed 
higher G-score and good binding pose.  
The phenyl ring with F or CH3 groups at Ar position helps the 
oxazole derivatives to form the hydrophobic contacts with 
surrounding hydrophobic amino acids. The phenyl ring with F or 
CH3 groups also supports aliphatic side chain at C5 position or 
forming an H-bond with surrounding amino acids. Thus, the 
replacement of these hydrophobic substituents by other aryl ring 
substituents and hetero ring showed the decreased binding 
affinity toward COX-2 enzyme and G-score (fig 4 and fig 5). Table 5 
also clearly suggests that the replacement of hydrophobic 
substitution by hetero ring or phenyl ring with an electron 
withdrawing group at Ar position showed decrease in 
hydrophobic enclosure reward as well as lipophilic Vander Waal 
interaction and ultimately affect binding pose of compounds and 
reduces the G-score. These F or CH3 substituted phenyl ring in an 
above compound is surrounded by common hydrophobic amino 
acids Val 523, Phe 381, Leu 352, Ala 527, Phe 518, Leu 384, Tyr 
385 and Met 522. 
 
 
Fig. 1: Docking pose of celecoxib in active site of COX-2 enzyme
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1 Celecoxib -10.5 -1.3 -6.1 -1.5 13 3l -10.58 -1.32 -2.7 -6.38 
2 3a -10.36 -0.99 -2.7 -6.38 14 m -9.68 -1 -2.64 -5.96 
3 3b -9.29 -0.99 -2.19 -6.02 15 3n -7.91 -0.99 -1.51 -5.36 
4 3c -6.7 -1.31 -1.2 -5.25 16 3o -5.66 -1 -1.21 -3.66 
5 3d -7.08 -0.66 -1.71 -5.94 17 3p -5.29 0 -2.43 -6.71 
6 3e -7.26 -0.65 -0.74 -5.53 18 3q -9.05 -1 -2.14 -5.72 
7 3f -8.78 -0.33 -2.24 -6.01 19 3r -10.18 -1 -2.46 -6.61 
8 3g -10.28 -1.31 -2.61 -6.3 20 3s -5.04 -1.58 -2 -5.62 
9 3h -4.13 -0.99 -1.93 -4.79 21 3t -4.49 -1.58 -1.97 -4.55 
10 3i -2.53 0 -1.03 -4.85 22 3u -2.93 0 -1.58 -4.88 
11 3j -2.75 0 -1.58 -4.61 23 3v -2.38 0 -1.23 -4.76 
12 3k -2.74 0 -1.29 -5  
H Bond: Chem score hydrogen bond pair term. Lipophilic EvdW: Chem score lipophilic pair term and fraction of total protein ligand vanderwall 
energy. Phob En: Hydrophobic enclosure reward. 
 
 
Fig. 2: 2D Ligand interaction diagram of compound 3g, pink 
dotted bond indicate hydrogen bonding of ligand with side chain 
of amino acids, green bond indicate π-π stacking and dual colour 
bond indicate salt bridge 
 
 
Fig. 3: 2D Ligand interaction diagram of compound 3l, pink 
dotted bond indicate hydrogen bonding of ligand with side chain 
of amino acids, green bond indicate π-π stacking and dual colour 
bond indicate salt bridge 
 
CONCLUSION 
Twenty two compounds were synthesized and screened for anti-
inflammatory with analgesic and nitric oxide-releasing activity. 
Docking study of these synthesized compounds was also performed. 
Most of the compounds exhibited significant anti-inflammatory with 
analgesic and nitric oxide releasing properties. Compounds 3a, 3c, 
3g, 3l and 3r exhibited most prominent and constituent anti-
inflammatory activity. Compounds 3a, 3g, 3l and 3r showed strong 
analgesic activity. From the detailed analysis of the results of 
pharmacological studies, we conclude that the synthesized 
compounds have not only retained but showed enhanced anti-
inflammatory profile. Also, all the synthesized derivatives exhibited 
significant vaso relaxant activity. Therefore, it can be concluded that 
the rational, based on which these NCEs were designed, has been 
proven to be superior compared to the currently used NSAIDs. 
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